HK1258689A1 - 氨基噻唑化合物及其用途 - Google Patents
氨基噻唑化合物及其用途Info
- Publication number
- HK1258689A1 HK1258689A1 HK19101067.5A HK19101067A HK1258689A1 HK 1258689 A1 HK1258689 A1 HK 1258689A1 HK 19101067 A HK19101067 A HK 19101067A HK 1258689 A1 HK1258689 A1 HK 1258689A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- aminothiazole compounds
- aminothiazole
- compounds
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291667P | 2016-02-05 | 2016-02-05 | |
| PCT/US2017/015765 WO2017136315A1 (en) | 2016-02-05 | 2017-01-31 | Aminothiazole compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1258689A1 true HK1258689A1 (zh) | 2019-11-15 |
Family
ID=59496120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19101067.5A HK1258689A1 (zh) | 2016-02-05 | 2019-01-22 | 氨基噻唑化合物及其用途 |
Country Status (9)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170098A (es) | 2010-05-20 | 2017-07-17 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de quinasa trk |
| CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| EP3801529B1 (en) | 2018-05-25 | 2023-10-11 | OncoCube Therapeutics LLC | Highly potent tacc3 inhibitor as a novel anticancer drug candidate |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| EP4323351A1 (en) * | 2021-04-12 | 2024-02-21 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| TW202400575A (zh) | 2022-03-24 | 2024-01-01 | 美商Ａ２Ａ製藥公司 | 治療癌症的組合物和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000062778A1 (en) * | 1999-04-15 | 2000-10-26 | Bristol-Myers Squibb Co. | Cyclic protein tyrosine kinase inhibitors |
| AU2002231139B2 (en) * | 2000-12-21 | 2007-03-22 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| JP2006507302A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
| US20090105250A1 (en) * | 2005-01-26 | 2009-04-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| KR101579999B1 (ko) | 2008-04-21 | 2015-12-23 | 타이젠 바이오테크놀러지 컴퍼니 리미티드 | 헤테로사이클릭 화합물 |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| PL2604601T3 (pl) | 2010-08-10 | 2016-09-30 | Związek heteropierścieniowy | |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| EP2771337B1 (en) | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
| CN104024246B (zh) * | 2012-03-27 | 2016-03-02 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
-
2017
- 2017-01-26 TW TW106103165A patent/TWI620748B/zh active
- 2017-01-30 US US15/419,183 patent/US10047078B2/en active Active
- 2017-01-31 WO PCT/US2017/015765 patent/WO2017136315A1/en active Application Filing
- 2017-01-31 CN CN201780010118.4A patent/CN109069504B/zh active Active
- 2017-01-31 ES ES17747997T patent/ES2909612T3/es active Active
- 2017-01-31 KR KR1020187024997A patent/KR102449712B1/ko active IP Right Grant
- 2017-01-31 EP EP17747997.9A patent/EP3411035B1/en active Active
- 2017-01-31 JP JP2018560435A patent/JP6883049B2/ja active Active
-
2019
- 2019-01-22 HK HK19101067.5A patent/HK1258689A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20170226100A1 (en) | 2017-08-10 |
| CN109069504B (zh) | 2022-06-28 |
| JP2019511564A (ja) | 2019-04-25 |
| JP6883049B2 (ja) | 2021-06-02 |
| ES2909612T3 (es) | 2022-05-09 |
| EP3411035A1 (en) | 2018-12-12 |
| KR20180132618A (ko) | 2018-12-12 |
| EP3411035B1 (en) | 2022-03-02 |
| KR102449712B1 (ko) | 2022-09-30 |
| US10047078B2 (en) | 2018-08-14 |
| CN109069504A (zh) | 2018-12-21 |
| EP3411035A4 (en) | 2019-08-14 |
| WO2017136315A1 (en) | 2017-08-10 |
| TWI620748B (zh) | 2018-04-11 |
| TW201728583A (zh) | 2017-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258689A1 (zh) | 氨基噻唑化合物及其用途 | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL264258B (en) | Diazahetero-bicyclic substituted compounds and their use | |
| GB201714745D0 (en) | New compounds and uses | |
| KR102061390B9 (ko) | 구아니딘 화합물 및 그의 용도 | |
| GB201714740D0 (en) | New compounds and uses | |
| GB201714734D0 (en) | New compounds and uses | |
| IL292488B1 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| GB201616439D0 (en) | Compounds and uses | |
| IL267626B1 (en) | Teraaryl compounds and their uses | |
| GB201714736D0 (en) | New compounds and uses | |
| HK1258687A1 (zh) | 噻唑烷酮化合物及其用途 | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| IL292482B1 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201614224D0 (en) | Compounds and uses thereof | |
| IL265617B (en) | 1-phenylpropanone compounds and their use | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201714743D0 (en) | New compounds and uses | |
| GB201712049D0 (en) | Novel compounds and their use | |
| GB201613134D0 (en) | Novel compounds and their use | |
| GB201614874D0 (en) | New compounds and uses | |
| HUP1600286A2 (en) | Fungicidal composition and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHRG | Changes in the register |
Free format text: CORRECTION OF THE NAME OF THE INVENTOR: FROM HSU, TSU Free format text: CORRECTION OF THE NAME OF THE INVENTOR: FROM JIAANG, WEIR-TOM |